The Gut Microbiota and Respiratory Diseases: New Evidence

Human body surfaces, such as the skin, intestines, and respiratory and urogenital tracts, are colonized by a large number of microorganisms, including bacteria, fungi, and viruses, with the gut being the most densely and extensively colonized organ. The microbiome plays an essential role in immune s...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2020, Vol.2020 (2020), p.1-12
Main Authors: Jianbing, Pan, Yanxia, Lin, Haiyue, Liu, Chunxi, Li, Jin, Su
Format: Article
Language:English
Subjects:
Allergies
Antibiotics
Arthritis
Asthma
Autoimmune diseases
Bacteria
Breastfeeding & lactation
Chronic obstructive pulmonary disease
Cystic fibrosis
Digestive system
Dysbacteriosis
Fungi
Gastrointestinal diseases
Gastrointestinal tract
Health care
Homeostasis
Immune response
Immune system
Immunology
Infections
Inflammation
Inflammatory bowel disease
Intestinal microflora
Lung cancer
Lung diseases
Microbiomes
Microbiota
Mortality
Obstructive lung disease
Probiotics
Respiratory diseases
Review
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human body surfaces, such as the skin, intestines, and respiratory and urogenital tracts, are colonized by a large number of microorganisms, including bacteria, fungi, and viruses, with the gut being the most densely and extensively colonized organ. The microbiome plays an essential role in immune system development and tissue homeostasis. Gut microbiota dysbiosis not only modulates the immune responses of the gastrointestinal (GI) tract but also impacts the immunity of distal organs, such as the lung, further affecting lung health and respiratory diseases. Here, we review the recent evidence of the correlations and underlying mechanisms of the relationship between the gut microbiota and common respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), lung cancer, and respiratory infection, and probiotic development as a therapeutic intervention for these diseases.
ISSN:2314-8861
2314-7156
DOI:10.1155/2020/2340670